by Robert Baden-Powell | Jan 5, 2020. We did continue to grow robustly in the quarter.

Rice, I had two questions. The COVID-19 pandemic affected people with advanced kidney disease. Funeral arrangement under the care ofSTORKE , NASH & SLAW FUNERAL HOME. This is Michael Jungling, Morgan Stanley.

So we did see -- on the outset of COVID, we did that elective procedures slowed because it was used kind of deemed to be part of the overall elective surgery hold with some -- a lot of great discussions very early on. And can you maybe separate the two items? There will be some element of critical care pay where we pulse our needs and our spend in that current hotspots that we are seeing in the United States. But as most things in life, we'll have to wait and let it come to us and see how it looks in the future. Have a great summertime to the extent you can enjoy. There are no additional photos for Robert Lewis Powell Sr. at this time. https://www.legacy.com/obituaries/sunsentinel/obituary.aspx?pid=196301786 The other thing that's hard for everybody when you get into the developing world is really understanding when someone unfortunately passed, was it exactly due to COVID or what was the real cause. We are sad to announce that on September 16, 2020 we had to say goodbye to Robert Lewis Powell Sr. of King George, Virginia.
So there are members that are going to be living with ESRD. So again, I say we are comfortable with where we sit and how we think this will unfold over time. That's just one example. So Patrick, here's how we're thinking about this. Yes, Falko, it's Rice. The direct eligible expenses in the U.S. are mitigated by the CARES Act funding, including the temporary sequestration relief. So yes, I feel we've got some real strong underlying performance there. Again, this quarter, significantly unfavorable foreign currency translation effects had a negative impact on our operational performance. Rice has already outlined the solid revenue development. So I'll take your first question on Medicare Advantage. In the Asia Pacific region, postponement of elective procedures due to the pandemic, impacted the Care Coordination business in Australia.

So hence the question. Thanks, Rice. So I think it's a combination of both. I can say that in Q2, Medicare Advantage was still the fastest-growing book of business that we had. Let me just add one point because this is happening in real time to what I think is a great answer Helen gave you. I think it's going great. And a great example of that is we believe Humana is one of the plans -- it's at the forefront of innovation, and we have extended our contract with them. As discussed, the sizable negative impact from COVID-19 in our first quarter results reversed in Q2, making it a positive driver in Q2 but neutral in half 1, mainly due to the timing of CARES Act funding for direct eligible expenses and the net valuation effect. I think I remember Q3 last year as well, it was very significant. Oliver, I'll take those. Content approved and certified by a member of the Echovita supervisory team. Family and friends can send flowers and/or light a candle as a loving gesture for their loved one. We had such fun at hunting events with Bobby and Ann. So figure, 165 max, if we get everything done this year and an incremental 100. I guess you have also some other stake like the Vifor JV, and we never revalue that stake, for example. (71 years old).

Sure. I would also tell you that as we engage politically with both sides of the House and understanding what people's platform is going to be, that is not the #1 priority that we -- that I personally think the Biden campaign is going to be looking at. [Operator Instructions]. And we are seeing -- we're seeing growth there. Please accept Echovita’s sincere condolences. The next question comes from the line of Christoph Gretler with Crédit Suisse.

It's obviously what caused the Latin America impairment trigger as well because of the change in the economic situation in Latin America where a lot of those sovereign rates change, too. 99. Echovita offers a solidarity program that gives back the funds generated to families. But you generally see -- in China, you see a lot of home, I think in Malaysia and Thailand as well. Can you hear me?

So how does that translate into the numbers? I just wanted to kind of ask a bigger picture question. Thank you, Dominik. I'm just curious if you can help us sort of work through some of the sort of scenarios around that, that would be really helpful. Turning to Slide 6. (81 years old).

And we've had the first really a bit of bad news, came from the CCX140 Phase II trial where the data just did not show efficacy that we were looking for in terms of treating Focal Segmental Glomerulosclerosis, which is basically a situation where you've got a part of your glomeruli do the filtration, they don't work. Robert is currently 76 years old. I think a bigger concern and just thinking our way through, it would be tax reform. Great, great. Our strong performance in the second quarter and the first half of this year proves that our core value proposition and the resilience of our business model is well-founded.

Paperback $19.99 $ 19. I have two questions, please. And we -- if things get completely locked down, we could have an impact. And then maybe a follow-up for Rice. I just have the fear that we end up like with ESCO, as a disagreement on what the cost savings were and then we go into this prolonged debate and negotiations, which is not particularly helpful. And we will see that most probably in the very first days of November. In the Asia Pacific region, we saw muted development due to the mentioned negative impact of COVID-19 in the Care Coordination business in Australia. And you can't really come to that kind of an extension in that agreement, on what the future state through value-based care can be if you don't have a good relationship and a good history. So Rice, if you can share your expectations on that, that would be very helpful. So we're up and running with that. But at this point in time, we are still seeing continued small improvements in our commercial mix. So here's sort of what we see. It's apparently very volatile so makes our life more difficult.

But quite honestly, for all the years that I've been associated with the Vifor JV, this is really 1 bit of bad news that we've gotten.
If you recall, they were our patients, they would come in, they'd tell us they want to go home, they have the ability to see what kind of technology they want to use. Particularly today, right? Please accept Echovita’s sincere condolences. 0. We had to manage quite different challenges caused by COVID-19 and our regional organizations. 7, 2020. His character got people referring to him the real Jesus who lived and died 2,500 years ago. In Europe, we finished up the integration with NxStage. Did you want -- yes, okay. I think hopping into tax reform and putting that on the back of corporations when we really haven't recovered, you see kind of where we are today with GDP in the U.S. As we think about our outlook, we know that we still have CARES money still to allocate against those direct expenses that are eligible for the relief. And minority interest? I think we have this volatility in operating earnings from that for quite a while. We are committed to provide the best possible outcomes for our patients on a worldwide basis. And that is triggered by some terrific focus on our cash flow. In EMEA, we realized a solid organic and same market growth resulting in 4% constant currency growth. We have argued with the government, as you well know, and we have not been overly successful. And they have to make that decision of in-center or home.

Our operational strength continued despite the impact of COVID-19. Do you think [indiscernible] are fairly uniform? I will now move on to our cash flow slide. Or is it manageable with what we know today? This increase was driven by the operational underlying performance supported by lower costs for pharmaceuticals, improved commercial mix as well as our ongoing cost saving measures. The other point I would like to make is, I know everyone assumes that the relationships between us and payers must be terrible, and I keep telling you they're not. With sort of mid to high single digit both at the top and bottom line, I'm just curious if some of the moving pieces. 4.7 out of 5 stars 5. The wide-ranging measures that we took at a very early stage to ensure the continuity and quality of care for our patients continues to bode well for Fresenius Medical Care. So I think it's a little bit of night and day, Michael, as to how those relationships will progress and evolve. Just curious how you sort of think that could impact growth as we get through the rest of the year. Helen has more detail for you in her prepared remarks. Unfortunately, there are no events for Robert Lewis Powell Sr. at this time. What we don't know, and a lot of this is going to depend on what a second surge should look like, particularly in Q4 is, are we going to be back in a complete lockdown? Ann, my thoughts & prayers are with you & the family.

Now it is my very big pleasure as always to start out the call by mentioning our cautionary language that is in our safe harbor statement as well as in our presentation and in all the materials that we have distributed earlier today. And they really aren't. We delivered both in the services business and the products business. And perhaps some indication of what the negative impact in Q1 was and the positive impact in Q2? Our cash flow focus and deleverage targets continue to be a key priority for me. Robert E. “Bob” Powell, 91, of Centralia passed away surrounded by the love of his family on Saturday, August 29, 2020.